A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Condition: Mesothelioma
MeSH terms: Mesothelioma; Mesothelioma, Malignant
Intervention: Tremelimumab; Durvalumab
Intervention description: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.; Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
Intervention MeSH terms: Durvalumab; Tremelimumab
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 19.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Mesothelioma

Summary:

      This research study is studying a pair of immunotherapies as a possible treatment for
      malignant pleural mesothelioma.

      The drugs involved in this study are:

        -  Durvalumab

        -  Tremelimumab
    

Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent obtained prior to any study-specific procedures not
             considered part of routine medical care

          -  Histologically or cytologically confirmed unresectable or medically inoperable
             malignant pleural mesothelioma

          -  Disease progression after treatment with at least one line of chemotherapy that
             included a first-line platinum agent in combination with an anti-folate

          -  Participants must have measurable disease according to modified RECIST for pleural
             malignant mesothelioma. (Bone metastases are not considered measurable.) Prior
             radiation to the only site of measurable disease will make the participant ineligible
             unless the lesion has been demonstrated to grow after completion of radiation therapy.

          -  Participants must be willing and able to undergo a biopsy at the start of this study
             and an on-treatment biopsy if safe and feasible.

          -  Participants must have be at least 28 days from any major surgery.

          -  ECOG performance status of 0 or 1.

          -  Subjects must have adequate hematologic, renal, and organ and marrow function

          -  Age 18 years or older

          -  Female subjects of childbearing potential who are sexually active with a non
             sterilized male partner must agree to use at least one highly effective method of
             contraception from the time of screening and must agree to continue using such
             precautions for 180 days after the last dose of investigational product. Male partners
             of a female subject must also agree to use male condom plus spermicide throughout this
             period. Cessation of birth control after this point should be discussed with a
             responsible physician. Not engaging in sexual activity for the total duration of the
             trial and the drug washout period is an acceptable practice; however, occasional
             abstinence, the rhythm method, and the withdrawal method are not acceptable methods of
             contraception. Female patients should refrain from breastfeeding throughout this
             period.

          -  Females of childbearing potential are defined as those who are not surgically sterile
             (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or
             post-menopausal (defined as greater than or equal to 12 months with no menses without
             an alternative medical cause)

          -  Non-sterilized male subjects who are sexually active with a female partner of
             childbearing potential must use male condom plus spermicide from screening through 180
             days after the last dose of investigational product. Not engaging in sexual activity
             for the total duration of the trial and the drug washout period is an acceptable
             practice; however, occasional abstinence, the rhythm method, and the withdrawal method
             are not acceptable methods of contraception. Male patients should refrain from sperm
             donation throughout this period. Female partners of a male subject must use a highly
             effective method of contraception throughout this period.

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Subject is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up

        Exclusion Criteria:

          -  Previous treatment with an immune check-point inhibitors, CTLA-4, PD-1, or PD-L1,
             including prior treatment with either durvalumab or tremelimumab

          -  Known central nervous system metastasis. Patients with known brain metastases, spinal
             cord compression, carcinomatous meningitis, or leptomeningeal disease may be enrolled
             if they have been treated, are no longer taking corticosteroids, and have been stable
             on imaging for at least 3 weeks

          -  Subjects currently receiving systemic corticosteroids above 10 mg per day for more
             than 14 days; subjects receiving other systemic immunosuppressive drugs for more than
             14 days. Exceptions include: inhaled, intranasal, ophthalmic, and topical
             corticosteroids, local corticosteroid injections (e.g., intra-articular injections),
             and subjects requiring corticosteroid pre-medication for hypersensitivity reactions
             (e.g. CT scan premedication)

          -  Subjects with medical conditions that require the chronic use of systemic
             corticosteroids. Exceptions include: inhaled, intranasal, ophthalmic, and topical
             corticosteroids, local corticosteroid injections (e.g., intra-articular injections),
             and subjects requiring corticosteroid pre-medication for hypersensitivity reactions
             (e.g. CT scan premedication)

          -  Active or prior documented autoimmune disease within the past 2 years, including but
             not limited to systemic lupus erythematosus, sarcoidosis syndrome, or Wegener's
             granulomatosis. NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not
             requiring systemic treatment within the past 2 years are not excluded.

          -  Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis, celiac disease, diverticulitis), or any other chronic, serious
             gastrointestinal condition associated with diarrhea. NOTE: Subjects with known
             diverticulosis are permitted to enroll.

          -  History of interstitial lung disease or pneumonitis that has required steroid
             administration.

          -  History of primary immunodeficiency

          -  History of allogeneic organ transplant

          -  History of hypersensitivity to tremelimumab, durvalumab, or any excipient

          -  Known history of active tuberculosis

          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving durvalumab or tremelimumab

          -  Participants with a history of a second primary malignancy. Exceptions include:
             patients with a history of malignancies that were treated curatively and have not
             recurred within 5 years prior to study entry; resected basal and squamous cell
             carcinomas of the skin, and completely resected carcinoma in situ of any type.

          -  Participants who have had chemotherapy, biologic therapy, or investigational therapy
             within 21 days (including bevacizumab) or radiotherapy within 7 days prior to entering
             the study or those who have not recovered from adverse events due to agents
             administered

          -  Any history of a prior immune-related adverse event (irAE) at least or greater than
             grade 3 while receiving any previous immunotherapy agent.

          -  Participants who are receiving any other investigational agents.

          -  Uncontrolled intercurrent illness including, but not limited to:

               -  Ongoing or active infection

               -  Gastritis

               -  Symptomatic congestive heart failure

               -  Severe hypertension (defined as BP at least or greater than160/100 during the
                  screening period despite optimal medical management)

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Active bleeding diatheses

               -  Active peptic ulcer disease

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements

          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
             electrocardiograms (ECGs) using Fredericia's Correction

          -  Known past or present medical history HIV-positive

          -  Subjects with known acute or chronic hepatitis B or hepatitis C.

          -  Pregnant women are excluded from this study because tremelimumab and durvalumab have
             unknown effects on the developing fetus. Because there is an unknown but potential
             risk for adverse events in nursing infants secondary to treatment of the mother with
             tremelimumab or durvalumab, breastfeeding women are also excluded. Female subjects of
             child bearing potential must have a negative serum pregnancy test obtained prior to
             trial registration.

          -  Subjects who are involved in the planning and/or conduct of the study (applies to both
             AstraZeneca staff and/or staff at the study site).

          -  Subjects who have undergone a pneumonectomy due to known potential for pulmonary
             toxicities and heightened risk for complications.